SCHEMBL6156471

SCHEMBL6156471

CN(c1ccc(C(N)=O)cc1)C1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 4/20 0.40
LCK P06239 3/20 0.40
MEN1 O00255 1/20 0.40
CYP2D6 P10635 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC6A4 P31645 3/20 0.39
KCNH2 Q12809 1/20 0.38
OPRD1 P41143 2/20 0.38
PARP10 Q53GL7 3/20 0.37
PARP2 Q9UGN5 2/20 0.36
PARP15 Q460N3 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
CYP2C9 P11712 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
PARP1 P09874 1/20 0.36
PARP4 Q9UKK3 1/20 0.36
HTR1D P28221 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4683664 0.86 MEN1 (0.42) JAK3LCKMEN1CYP2D6KMT2A
SCHEMBL18361035 0.82 NOTUM (0.46) MEN1KMT2AOPRD1CA1CA2
SCHEMBL5487069 0.79 SLC6A4 (0.51) SLC6A4OPRD1SLC6A2SLC6A3PARP1
SCHEMBL1866454 0.78 ALDH1A1 (0.43) MEN1CYP2D6KMT2ASLC6A4SLC6A2
SCHEMBL2477882 0.78 USP7 (0.36) MEN1CYP2D6KMT2ASLC6A4SLC6A2
SCHEMBL6154768 0.77 SLC6A4 (0.42) JAK3MEN1CYP2D6KMT2ASLC6A4
SCHEMBL4577662 0.76 SLC6A4 (0.46) MEN1CYP2D6KMT2ASLC6A4SLC6A2
SCHEMBL6153634 0.76 PARP15 (0.44) MEN1KMT2ASLC6A4PARP10PARP15
SCHEMBL2092295 0.75 NOS2 (0.44) SLC6A4SLC6A2SLC6A3
SCHEMBL26011715 0.75 NMT1 (0.35) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 JAK3 2272/4885LCK 1636/4885MEN1 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.